18,500 Shares in Novo Nordisk A/S (NYSE:NVO) Purchased by Sava Infond d.o.o.

Sava Infond d.o.o. acquired a new stake in shares of Novo Nordisk A/S (NYSE:NVO) during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 18,500 shares of the company’s stock, valued at approximately $1,591,000.

A number of other institutional investors also recently added to or reduced their stakes in NVO. Menard Financial Group LLC lifted its holdings in Novo Nordisk A/S by 0.8% during the 3rd quarter. Menard Financial Group LLC now owns 12,283 shares of the company’s stock valued at $1,463,000 after purchasing an additional 102 shares during the last quarter. Optimist Retirement Group LLC raised its stake in shares of Novo Nordisk A/S by 4.3% in the third quarter. Optimist Retirement Group LLC now owns 2,747 shares of the company’s stock valued at $327,000 after acquiring an additional 112 shares during the last quarter. Financial Counselors Inc. boosted its holdings in shares of Novo Nordisk A/S by 1.1% in the 3rd quarter. Financial Counselors Inc. now owns 11,009 shares of the company’s stock worth $1,311,000 after acquiring an additional 115 shares in the last quarter. M. Kulyk & Associates LLC grew its position in Novo Nordisk A/S by 3.9% during the 4th quarter. M. Kulyk & Associates LLC now owns 3,182 shares of the company’s stock worth $274,000 after acquiring an additional 119 shares during the last quarter. Finally, Center for Financial Planning Inc. increased its holdings in Novo Nordisk A/S by 72.4% during the 4th quarter. Center for Financial Planning Inc. now owns 293 shares of the company’s stock valued at $25,000 after purchasing an additional 123 shares in the last quarter. 11.54% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research firms have commented on NVO. Morgan Stanley began coverage on Novo Nordisk A/S in a research note on Wednesday, February 12th. They issued an “equal weight” rating on the stock. BMO Capital Markets reduced their price target on shares of Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating on the stock in a research report on Monday, December 23rd. Sanford C. Bernstein raised shares of Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a research note on Monday, January 6th. StockNews.com cut shares of Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research note on Friday, March 21st. Finally, BNP Paribas upgraded shares of Novo Nordisk A/S to a “strong-buy” rating in a research report on Monday, December 2nd. Three analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $145.25.

Novo Nordisk A/S Trading Down 2.5 %

NVO opened at $71.74 on Thursday. The firm has a 50 day simple moving average of $82.78 and a 200 day simple moving average of $99.75. Novo Nordisk A/S has a fifty-two week low of $70.09 and a fifty-two week high of $148.15. The company has a market cap of $321.94 billion, a price-to-earnings ratio of 21.81, a price-to-earnings-growth ratio of 0.90 and a beta of 0.42. The company has a debt-to-equity ratio of 0.62, a current ratio of 0.74 and a quick ratio of 0.55.

Novo Nordisk A/S (NYSE:NVO) last issued its earnings results on Wednesday, February 5th. The company reported $0.91 EPS for the quarter, beating the consensus estimate of $0.88 by $0.03. Novo Nordisk A/S had a net margin of 34.81% and a return on equity of 84.68%. On average, sell-side analysts anticipate that Novo Nordisk A/S will post 3.84 earnings per share for the current year.

Novo Nordisk A/S Increases Dividend

The business also recently announced a semi-annual dividend, which will be paid on Tuesday, April 8th. Stockholders of record on Monday, March 31st will be given a dividend of $0.7874 per share. This is a positive change from Novo Nordisk A/S’s previous semi-annual dividend of $0.51. This represents a dividend yield of 1.2%. The ex-dividend date is Monday, March 31st. Novo Nordisk A/S’s payout ratio is presently 47.72%.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.